Trump Administration's FDA Considers Dropping Expert Drug Review Panels

In a shift in longstanding procedure, FDA leadership under President Trump is contemplating the removal of advisory panels composed of external specialists to assess new drug applications. Critics warn that this could limit public insight into agency decisions.

George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research, indicated the agency's interest in eliminating these panels, stating they may no longer be necessary. He communicated this perspective at meetings with healthcare manufacturers and advocacy groups.

Rationale and Criticism

Tidmarsh argued that the meetings engage significant effort from FDA and corporations on issues he classifies as not requiring such focus. Instead, he suggests redirecting energy to broader regulatory questions.

These expert panels, embedded in the FDA's processes since a 1972 legislation, provide input and votes on tough drug approval decisions. Typically, the agency follows their recommendations, but deviations, like the one with Biogen's Alzheimer's treatment in 2021, stir debate.

Transparency Versus Advisory Panels

The FDA has recently begun publishing 'complete response letters' when it turns down drug applications, which Tidmarsh contends maintain transparency akin to that provided by advisory meetings.

However, former FDA officials and academic experts challenge this viewpoint, stressing that advisory meetings offer unique public visibility into FDA's deliberations, enhancing comprehensive understanding.

Expert Opinions

Doubts over Tidmarsh's reasoning were expressed by former FDA Commissioner Robert Califf, who believes open discussions with experts advance decision-making and transparency in public health.

Similarly, Holly Fernandez Lynch from the University of Pennsylvania highlights the opportunity these meetings offer for public engagement and scrutiny, which can't be replaced by documentation alone.

Controversy and Strategic Shifts

Despite claims of redundancy, critics argue removing these panels consolidates power, potentially side-lining independent expertise.

Given the reduction in advisory panels since Trump re-entered office, some observers speculate this may be a strategic maneuver rather than temporary, geared towards minimizing external accountability.